Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

Y0000522

Norethisterone for system suitability

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
19-Norethindrone, 17α-Ethynyl-19-nortestosterone, 17-Hydroxy-19-nor-17α-4-pregnen-20-yn-3-one, 17α-Ethynyl-17β-hydroxy-19-nor-4-androsten-3-one, 19-Nor-17α-ethynyl-4-androsten-17β-ol-3-one, 19-Norethisterone
Empirical Formula (Hill Notation):
C20H26O2
CAS Number:
68-22-4
Molecular Weight:
298.42
Beilstein:
1915671
MDL number:
MFCD00067596
UNSPSC Code:
41116107
PubChem Substance ID:
329831003
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

norethisterone

manufacturer/tradename

EDQM

mp

205-206 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4(O)C#C

InChI

1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

InChI key

VIKNJXKGJWUCNN-XGXHKTLJSA-N

Gene Information

human ... PGR(5241)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Norethisterone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

19-norethindrone is an oral contraceptive involved in the inhibition of cytosolic sulfotransferases (SULT).

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazardEnvironment
GHS08,GHS09

Signal Word

Danger

Hazard Statements

H351,H360FD,H362,H410

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 1A

WGK

WGK 3

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Karl van den Broeck et al.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 17(5), 321-328 (2012-09-15)
Ferdinand Peeters, a practising gynaecologist from Turnhout, near Antwerp (Belgium), had a pivotal role in the development of a practical and viable modality of oral contraception, striking the balance between efficacy and an acceptably low incidence and severity of side
Isabelle Demeestere et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(7), 903-909 (2012-11-07)
To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. Patients age 18 to 45 years were randomly assigned
V Koskela-Niska et al.
Climacteric : the journal of the International Menopause Society, 16(1), 48-53 (2012-05-30)
While previous data link the use of postmenopausal hormone therapy to an increased risk for ovarian cancer, little is known about the impact of various progestins, modes or routes of administration of hormone therapy for this risk. In this nationwide
Louise Lind Schierbeck et al.
BMJ (Clinical research ed.), 345, e6409-e6409 (2012-10-11)
To investigate the long term effect of hormone replacement therapy on cardiovascular outcomes in recently postmenopausal women. Open label, randomised controlled trial. Denmark, 1990-93. 1006 healthy women aged 45-58 who were recently postmenopausal or had perimenopausal symptoms in combination with
Chelsea B Polis et al.
The Lancet. Infectious diseases, 13(9), 797-808 (2013-07-23)
Whether or not the use of hormonal contraception affects risk of HIV acquisition is an important question for public health. We did a systematic review, searching PubMed and Embase, aiming to explore the possibility of an association between various forms
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service